跳至主要内容
临床试验/NL-OMON38105
NL-OMON38105招募中不适用

Exploration of VEGF expression in paediatric high grade glioma and diffuse intrinsic pontine glioma using 89Zirconium-bevacizumab imaged by PET - 89Zr-Bevacizumab PET in pHGG & DIPG

Vrije Universiteit Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • - DIPG (MRI confirmed, biopsy not required) after radiotherapy
  • - De novo biopsy proven HGG with minimal residual tumor of 5 mm in each dimension
  • - pHGG & DIPG patients with progressive disease after radiotherapy
  • - Age between 4 and 18 years
  • - Able to lay down quiet for 30 minutes

排除标准

  • - Chemotherapy or radiotherapy in the past two weeks
  • - Previous administration of bevacizumab or another anti-VEGF drug
  • - Known hypersensitivity against humanized monoclonal antibodies
  • - Neurofibromatosis type I

研究者

相似试验